Hover a dot or row, or tab through the dots · bars scaled to the largest round ($275M)
Form D offerings
One line per offering, amendments folded in, newest first
Form D offerings
File
First filed
Latest
Sought
Sold
Investors
Exemptions
021-378335
First filed2020-10-20
Latest2020-10-20
Sought$275M
Sold$275M
Investors57
Exemptions506(b)
Who backs Nuvation Bio Inc. — 1 inferred investor — and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2020-10-20
Related persons
Name
Relationship
David Hung, M.D.
RelationshipExecutive Officer, Director
Kim Blickenstaff
RelationshipDirector
Michelle Doig
RelationshipDirector
Robert Bazemore
RelationshipDirector
Claudio Nessi
RelationshipDirector
W. Anthony Vernon
RelationshipDirector
Daniel Welch
RelationshipDirector
Kathryn E. Falberg
RelationshipDirector
Facts
As its latest Form D states them
Industry
Pharmaceuticals
State
New York (NY)
Exemptions
Rule 506(b)
First filed
2020-10-20
Latest filing
2020-10-20
Who backs Nuvation Bio Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
Inferred investors — the funds and firms behind it, from co-filings and shared people
Every Form D and amendment as filed, with what each one stated
Its rounds in sequence: the gap between them and whether they grew
Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)